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The strongest association between FMR1 and the ovary in humans is the increased risk
of premature ovarian failure (POF) in women who carry the premutation level of CGG
repeats (55–199 CGGs). Research on the FMR1 gene has extended to other endpoints of
relevance in the OB/GYN setting for women, including infertility and ovarian hormones.
After reviewing the nomenclature changes that have occurred in recent years, this article
reviews the evidence linking the length of the FMR1 repeat length to fertility and
ovarian hormones (follicle stimulating hormone and anti-mullerian hormone as the primary
methods to assess ovarian reserve in clinical settings). The literature is inconsistent on the
association between the FMR1 trinucleotide repeat length and infertility. Elevated levels
of follicle stimulating hormone have been found in women who carry the premutation;
however the literature on the relationship between anti-mullerian hormone and the CGG
repeat length are too disparate in design to make a summary statement. This article
considers the implications of two transgenic mouse models (FXPM 130R and YAC90R) for
theories on pathogenesis related to ovarian endpoints. Given the current screening/testing
recommendations for reproductive age females and the variability of screening protocols
in clinics, future research is recommended on pretest and posttest genetic counseling
needs. Future research is also needed on ovarian health measurements across a range of
CGG repeat lengths in order to interpret FMR1 test results in reproductive age women;
the inconsistencies in the literature make it quite challenging to advise women on their
risks related to FMR1 repeat length.
Keywords: FMR1, female infertility, primary ovarian insufficiency, mouse models, diminished ovarian reserve,
follicle stimulating hormone, anti-mullerian hormone, genetic counseling
FMR1 GENE OVERVIEW
The name “fragile X” refers to a cytogenetic abnormality on the
long arm of the X chromosome. The genetic focus of fragile
X research is the 5′-untranslated region of the fragile X mental
retardation 1 (FMR1) gene, located at Xq27.3.
The reference range for the FMR1 trinucleotide repeat length
has four categories. The trinucleotide repeat reference intervals
are based on studies designed to establish the diagnosis of Fragile
X Syndrome (FXS) and the associated risk of expansion to a full
mutation that occurs during transmission from a premutation
carrier mother to her offspring. FXS is the most common herita-
ble form of intellectual and developmental disabilities and autism.
The categories in order of increasing trinucleotide length are nor-
mal, intermediate, premutation, and full mutation. The CGG
repeat size corresponding to each diagnostic category generally
varies by ±5 repeats in the literature due to changing defini-
tions over time and differences in individual report categories.
The current categories are defined as follows:
• The American College of Obstetrics and Gynecology Genetics
Committee Report, the American College of Medical Genetics
(ACMG) Quality Assurance Committee and the ACMG
Technical Standards Report all explicitly state that an FMR1
CGG repeat length less than 45 is not associated with an abnor-
mal phenotype (Kronquist et al., 2008; ACOG Committee
of Genetics, 2010; Monaghan et al., 2013). Thus, <45 CGG
repeats is considered normal.
• Repeats in the range of 45–54 are termed intermediate or “gray
zone” or inconclusive (Maddalena et al., 2001; Kronquist et al.,
2008; Monaghan et al., 2013).
• Repeats in the range of 55–199 are termed “premutation”
(Maddalena et al., 2001; Kronquist et al., 2008).
• At least 200 CGG repeats is a “full mutation” and results in
FXS in the majority of boys and in some girls with this genetic
mutation. A gene with this CGG repeat level is typically hyper-
methylated, resulting in transcriptional silencing such that no
or only low levels of protein (FMRP) are produced (Oostra and
Willemsen, 2003).
In terms of clinical phenotypes that have been associated with this
gene, as stated above, full mutations can cause FXS. As research
demonstrated that many mothers of FXS boys were carriers of a
premutation-size allele, the importance of the premutation cat-
egory and potentially the intermediates became recognized by
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clinical authorities. This is reflected in statements by ACMG com-
mittee members: “the clinical significance of intermediate and
low premutation size alleles. . . is the extent to which they may
be prone to instability, particularly expansion, in future genera-
tions” (Kronquist et al., 2008). For a review of the mental health
impact of the FMR1 gene, both in terms of the affected individual
and their family, the reader is referred to Seltzer et al (Seltzer et al.,
2009).
The FMR1 gene has been associated with alterations of some
reproductive milestones. Most notable is the evidence that pre-
mutations are associated with premature ovarian failure (POF).
The FMR1 premutation is present in about 11% of familial POF
cases and about 3% of sporadic POF cases (Marozzi et al., 2000;
Murray et al., 2000; Bussani et al., 2004), although a recent report
from the United Kingdom suggests that only 2% of POF cases
have a premutation (Murray et al., 2014). The odds of being a
premutation carrier if the woman is postmenopausal before age
40 was recently estimated to be more than fivefold from that UK
report (Murray et al., 2014).
Following the confirmation of the association between the
FMR1 premutation and POF, publications appeared on the rela-
tionship between ovarian hormones, infertility and this gene. Not
surprisingly, the volume of research on hormones and fertility is
far smaller than the volume on POF, and this body of research is
the focus of this publication. Before we summarize the literature,
comments on nomenclature are warranted.
WHAT IS PRIMARY OVARIAN INSUFFICIENCY (POI)?
TERMINOLOGY AND CONFUSION
POF and diminished ovarian reserve (DOR) are clinical diag-
noses made by reproductive endocrinologists (Fritz and Speroff,
2011a,b); POF is also a recognized clinical diagnosis made by
endocrinologists in general (Jameson and DeGroot, 2010). POF is
diagnosed by three characteristics: postmenopausal levels of folli-
cle stimulating hormone (FSH) (>40 IU/L), 4 or more months
of secondary amenorrhea, and age <40 years (Coulam et al.,
1986). DOR is diagnosed by elevated FSH levels (>10 IU/L in
cycle days 2–4, or a failed clomiphene citrate challenge test) and
regular periods (Fritz and Speroff, 2011a), although some clinics
use anti-mullerian hormone and/or antral follicle count in their
assessment of ovarian reserve. DOR is a normal physiologic pro-
cess when it occurs in the mid to late forties, and is pathological
at younger ages.
Around 2007–2008, the term primary ovarian insufficiency
(POI) was suggested to represent a continuum of dysfunc-
tion related to early aging of the ovaries. Controversy exists as
to its precise definition, however. Some notable clinicians and
researchers (De Vos et al., 2010) have defined POI the same as
POF. The terminology of POI is considered to better represent
this condition, considering that there is a progression of ovar-
ian dysfunction that precedes the premature amenorrhea (Welt,
2008), as well as the fact that women with this condition some-
times spontaneously have follicular development and/or returned
menses and/or conceive after the diagnosis is made (Rebar and
Connolly, 1990; Nelson et al., 1994).
Other clinicians/researchers have suggested that POI repre-
sents a continuum of ovarian conditions that encompass an
“occult” clinical state (reduced fecundity but normal FSH levels
and regular menses), “biochemical” state (reduced fecundity,
elevated FSH and regular periods), and an “overt” state (approx-
imately corresponding to POF though perhaps with irregular
menses) (Welt, 2008).
It is interesting to note that neither ICD-9 nor ICD-10 medi-
cal coding systems use the POF or POI terminology. ICD-9 uses
the term “premature menopause” (code 256.31). For ICD-10,
there are 2 corresponding codes: E28.310 “Symptomatic pre-
mature menopause” and E28.319 “Asymptomatic premature
menopause.” The description of E28.310 is “Symptoms such as
flushing, sleeplessness, headache, lack of concentration, associ-
ated with premature menopause.” The description of E28.319
corresponds to the current ICD-9 code of 256.31. The billing code
for DOR in ICD-9 is 256.8 (“Other ovarian dysfunction”), and
this remains constant in ICD-10.
In terms of Index Medicus, “primary ovarian insufficiency” is
now a MESH term under the category of Ovarian Disease, as is
also true for “Premature Menopause.” There is not a MESH term
for DOR.
Clearly there are differences in terminology, which are beyond
the scope of this paper to resolve. This terminology is reviewed
here in a manner heretofore not discussed in the literature, in
order to address confusion among readers from disparate back-
grounds. For this publication, we will use the clinical diagnosis
terms of POF and DOR for the research on humans.
METHODOLOGIC ISSUES IN THE HUMAN FMR1 STUDIES
UNIT OF ANALYSIS
Two of the studies reviewed in Table 1 use alleles rather than
women as the unit of analysis. It is important for readers to note
whether a given report is estimating the allele frequency or the
carrier frequency in the interpretation of the results and when
comparing results across studies. For example, an analysis that
uses both alleles has the effect of inflating the sample size by
two, because all women contribute two chromosomes and, thus,
2 FMR1 alleles. Since the majority of alleles are in the normal
range, this approach will underestimate the frequency of inter-
mediate and premutation repeat lengths among women. It is not
possible to make a general statement on the impact on the statis-
tical significance of the findings that use both alleles rather than
one allele. We have noted via italics in Table 1 when a study used
alleles rather than the woman as the unit of analysis.
SAMPLE SELECTION
Much of the research on the premutation and ovarian function
derives from women with a family history of FXS. This is a practi-
cal population fromwhich to draw a sample given the enrichment
of premutation carriers in a family with a relative who has a full
mutation. However, the biology underlying familial cases vs. spo-
radic cases of a given phenotype may very well be different. [For
example, the likelihood of a premutation expanding to the full
mutation in a single generation is higher in families with a family
history of FXS than in families without a FXS relative (Nolin et al.,
2011)] Thus, the findings of each type of study sample should
be interpreted in the context of the population from which the
study sample was drawn, noting that findings from FXS family
studies may or may not extend to women without that family
history.
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Table 1 | Literature summary on FMR1 CGG repeat length among women diagnosed with fertility delays due to ovarian reserve issues, sorted
by year.
First author year;
country
Study sample description Key results
Streuli et al., 2009;
Switzerland
Source: infertility practices
Sample: 27 cases with low ovarian reserve (high FSH or low AMH
or poor response to stimulation) vs. 32 controls (referred for genetic
testing unrelated to fertility or mental impairment)
IM = 41–60 CGG
Note: Analysis compares allele frequencies, not carrier
frequencies.
Mean CGG length is higher in 27 cases (54 alleles, 33 CGG)
than controls (64 alleles, 28 CGG). Similar results for
biallelic mean.
Cases Control
NC 47 63
IM 4 (7.4%) 1 (1.6%)
PM 3 (5.6%) 0
Associations with IM and PM are not significant.
If dichotomize at >40 repeats, difference is significant;
OR = 9.4 (95% CI 1.1–81.2).
OR for 35–60 repeats is 5.4 (95% CI 1.1–25.6).
Gleicher et al.,
2009a; USA
Source: infertility clinic
Sample: 316 fertility clinic patients, stratified by CGG repeat.
Analyses independently considered lower and higher alleles.
The risk for low ovarian reserve (AMH ≤0.8 ng/mL)
increased by 40% for every +5 higher repeats above 30
CGGs on the higher allele (logistic regression adjusted for
age, p = 0.02).
Karimov et al., 2011;
USA
Source: infertility clinic
Sample: 535 cases with low ovarian reserve (elevated FSH, elevated
day 2–4 estradiol, poor response to stimulation)
vs. 521 controls (infertility unrelated to ovarian reserve, and oocyte
donors).
IM = 45–54 CGG
Carrier frequency of PM and IM more common in women
with low ovarian reserve than controls.
Cases Controls
PM 7 (1.3%) 1 (0.19%)
p = 0.036 (vs. NC)
IM 17 (3.2%) 7 (1.3%)
p = 0.046 (vs. NC)
Pastore et al., 2012;
USA
Source: infertility clinics
Sample: 62 cases with DOR (elevated FSH or <6 antral follicles),
age <42, regular menses, excluded family hx of FXS or PM.
Compared with 564 control women from literature [32 controls from
Streuli et al. (2009), 162 from Bretherick et al. (2005), 370 from
Otsuka et al. (2010), and 200 from Bodega et al. (2006)].
Carrier frequencies of 35–39 CGG and 40–44 CGG among
cases with DOR was significantly greater than literature
comparison groups.
35–44 CGGs
DOR 14.5%
Prior research 3.9% (p = 0.0003)
Barasoain et al.,
2013; Spain
Source: OB/GYN clinic patients
Sample: 22 cases with low ovarian reserve (irregular cycles,
elevated FSH)
vs. 7 women with POF
vs. 32 controls with no infertility and natural age at menopause
IM = 35–54 CGG
Note: Analysis compares allele frequencies, not carrier
frequencies.
Low ovarian reserve case group more likely to have ≥35
CGGs than controls (p < 0.05).
IM 35–54 PM
Cases 4/44 (9%) 2/44 (5%)
POF 3/14 (21%) 0/14
Controls 2/64 (3%) 0/64
De Geyter et al.,
2013; Switzerland
Source: Infertility patients (cases) and women with recent deliveries
(controls)
Sample: 372 cases with infertility (excluding male or tubal factor
infertility)
vs. 199 fertile women (recent birth and natural conception within 3
months)
IM (2 definitions analyzed )
IM and PM carrier frequencies not significantly different
between groups.
Infertile Fertile
NC 303 170
IM 35–44 55 (14.8%) 24 (12.1%)
IM 45–54 9 (2.4%) 4 (2.0%)
PM 5 (1.3%) 1 (0.5%)
PM, premutation; PMC, individual who carries the premutation; NC, non-carrier; POF, premature ovarian failure; DOR, diminished ovarian reserve; OR, odds ratio;
FSH, follicle stimulating hormone; AMH, anti-mullerian hormone; hx, history; dx, diagnosis; IM, individual with an intermediate repeat length.
RANGE OF REPEAT LENGTH UNDER INVESTIGATION
The research on FMR1 has also changed over time in the repeat
length of interest. The original research on FXS would, of course,
be focused on full mutations with >200 CGG repeat lengths.
When it was observed that there was a noticeable proportion
of the premutation carrier mothers experiencing POF, the focus
of some research shifted to the premutation range. With the
advent of consistent and affordable laboratory testing for the exact
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repeat lengths, the possibility of analyzing the entire repeat range
became the norm. The variation in the CGG repeat length of
interest between reports can cause confusion among clinicians
and patients regarding which genotype is or is not associated with
a given phenotype. Additionally, inconsistencies in the literature
may be due to differences in the repeat length being investigated
between different publications, so readers should be cognizant of
this issue.
LITERATURE ON INFERTILITY AND THE FMR1 GENE
The literature on the prevalence of FMR1 premutations in women
with DOR is still at a very early stage (Table 1). Among n = 65
US cases of DOR, 14% had a high normal (35–44 repeats) FMR1
CGG repeat length (Pastore et al., 2012). Their population had
regular menses and no family history of FXS, and neither anti-
Mullerian hormone (AMH) nor poor gonadotropin response was
used to define cases. The proportion of high normal carriers was
quite similar to a report from France (Streuli et al., 2009), where
17% of n = 27 women had 35–44 CGG repeats. In the French
publication, cases were defined as having regular or irregular
cycles (63/37%, respectively), FSH > 10 IU/L and/or AMH <
7 pmol/L and/or poor response to controlled ovarian hyperstim-
ulation, and no family history of FXS. Among 22 women with
DOR from Spain, 13.6% had ≥35 CGG repeats v 3.1% of the
normal controls (p < 0.05) (Barasoain et al., 2013). A US study
analyzed 535 women with a liberal definition of DOR (because
cases could have skipped only 3 periods) compared to 521 con-
trols (infertility from other causes or oocyte donors) (Karimov
et al., 2011). Premutations and intermediate alleles were more
commonly found in the cases than the controls (p = 0.036 and
p = 0.046, respectively). A different US study (Gleicher et al.,
2009a) reported an increased likelihood of DOR among women
seen in their large fertility clinic with <28 CGG repeats as well
as ≥34 repeats, with increasing risk the further there is an allele
from a modal repeat length of 29–30 CGG’s (p < 0.0002 among
a cohort of 316 consecutive fertility patients). Among 372 infer-
tile women from all causes (excluding those with complete tubal
infertility), a recent report found no difference in the repeat dis-
tribution compared with 199 fertile controls in Switzerland (De
Geyter et al., 2013). Clearly, it is still an outstanding question
whether or not the FMR1 gene is associated with low ovarian
reserve and infertility, and if it is, which repeat length confers the
greatest risk.
CLINICAL MARKERS FOR OVARIAN RESERVE (FSH AND
AMH) AND FMR1
FSH, a gonadotropin under negative feedback of two ovarian hor-
mones, inhibin B and estradiol (Burger, 1994, 2000), indirectly
reflects the quantity of the antral follicles. It may also provide
an indirect measure of the size or quality of the underlying fol-
licle pool (Goldenberg et al., 1973; Klein et al., 2000). As ovarian
function fails and the final menstrual period nears, the ovaries
produce less inhibin and estradiol, allowing levels of unopposed
FSH to rise (Burger et al., 2000). Among cycling women, early
follicular phase FSH begins to increase (indicating diminished
ovarian activity) beginning in the late 30 s to early 40 s (Kline
et al., 2005; van Rooij et al., 2005).
In a small but informative US study (Welt et al., 2004), daily
blood samples were examined for 1 month in 11 cycling premu-
tation carriers aged 24–41 years. Their comparison group was
22 age-matched cycling women without a suggestive family his-
tory of FXS; FMR1 testing was not conducted on the controls.
Compared with the controls, women with a premutation allele
had elevated FSH in both the follicular and luteal phases. Other
reports with single FSH measures have also reported that a pre-
mutation allele is associated with elevated FSH levels (Murray
et al., 1999; Hundscheid et al., 2001; Sullivan et al., 2005). No dif-
ferences in FSH (single measurement) was found between women
with a full mutation and those with <60 CGG repeats (Murray
et al., 1999). A recent report with 372 infertile women from all
causes, of whom 9 had an intermediate allele and 5 had a premu-
tation, reported no association between FSH and the CGG repeat
level (De Geyter et al., 2013). Among fertile women in the US
(Kline et al., 2014), there was no association between intermediate
alleles (defined as 35–54 CGG) and hormones (AMH and FSH) in
fertile women; These observations held true in their total sample
of 583 pregnancies, as well as when restricted to 325 pregnancies
that ended in a live birth.
AMH, also known as Mullerian-inhibiting substance, is a
dimeric glycoprotein. It is produced by Sertoli cells of the testis
in males and by ovarian granulosa cells in females. AMH is
increasingly used by clinicians to measure ovarian reserve in pre-
menopausal women and the volume of publications using AMH
measurements has significantly increased in the past 5 years. As
reviewed by Nelson and La Marca (Nelson and La Marca, 2011),
AMH has several unique characteristics, including that it appears
that circulating AMH in females is produced solely by the ovarian
granulosa cells from primary to small antral follicles (≤4–6mm)
(Weenen et al., 2004; Visser and Themmen, 2005). In a sample
of 42 ovaries obtained by oophorectomy, the age-adjusted corre-
lation between serum AMH and the natural log of the number
of primordial follicles was 0.48, supporting the view that AMH
reflects, in part, the size of the oocyte pool (Hansen et al., 2011).
Given that FMR1 is associated with early ovarian aging and
AMH is increasingly used as a measure of ovarian reserve, there
are now some publications that have investigated AMH levels by
FMR1 CGG repeat. The scant literature on the topic of AMH and
FMR1 (six publications that adjust for the woman’s age) is incon-
sistent. Three papers reported an inverse association between
AMH and FMR1 repeat after controlling for age. Among 158 con-
secutive cycling infertility patients (none of whom carried the
premutation) under age 40 at a single center in the US (Gleicher
et al., 2009b), AMHwas lower in women with 35–50 CGG repeats
(n = 35) than in women with <35 repeats (n = 122, p = 0.025).
Using a population that combined women from the general
female population and women with a family history of FXS in
the US, AMH was lower in women with ≥70 CGG repeats com-
pared to those with <70 repeats aged 31–40 years (p = 0.015);
No association was found among women over age 40 or ≤30
(p > 0.08) (Rohr et al., 2008), and this may be due to the exclu-
sion of women who were using hormone treatment. In a study
that combined FXS family data from The Netherlands and the
US, premutation carriers were found to have lower AMH levels
than non-carriers at all ages (multi-level modeling, p < 0.0001)
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(Spath et al., 2011); As expected, AMH declined with increas-
ing age among both premutation carriers and non-carriers. One
paper reported a positive association between AMH level and
FMR1 repeat length after controlling for age: among 197 Korean
women “at high risk” of diminished ovarian function, where the
highest CGG repeat was 51 (Choe et al., 2013), a positive cor-
relation was found between AMH and the CGG repeat length
(p = 0.008). Two recent papers reported no association: a recent
report with 372 infertile women from all causes reported no asso-
ciation between AMH and the CGG repeat level (De Geyter et al.,
2013), and the sample included some women with premutation
and intermediate length alleles. Among 532 fertile women in the
US (Kline et al., 2014), there was no association between interme-
diate repeat lengths (defined as 35–54 CGGs) and AMH. Recent
modeling by the authors (Pastore et al., 2014a), with data from
79 women with DOR in the US, found that a linear model of log
(AMH), corresponding to an exponential decline of AMH with
increasing age, was significantly different, and had a steeper slope,
for women with ≥35 CGG repeats than women with<35 repeats
(p = 0.035).
These FSH and AMH observations, while intriguing, have lim-
itations: studies are few; sample sizes are small; not all account
for the age of the woman; most use cross-sectional data; and
most studies exclude women who reached menopause, thereby
selecting for women who do not show the most severe effects
of the premutation. Differences in the results may be due to
the populations studied (FXS families, fertile women, or infertile
women).
ANIMAL MODELS RELEVANT TO THESE HUMAN
PHENOTYPES
Developing appropriate animal and cell models of ovarian effects
from the FMR1 gene are vitally important, as research in humans
is limited by the availability of specimens and participants, as
well as the practicality of harvesting tissues like the ovary for
analysis. Vertebrate (mouse and rat) and invertebrate (fruit fly;
Drosophila melanogaster) animal studies related to the FMR1 pre-
mutation and ovarian function exist and have been instrumental
in advancing our understanding of the disease phenotype, as
recently reviewed (Sherman et al., in review). Nonhuman pri-
mates (NHP) offer a clinically relevant model system in which to
explore the molecular mechanisms of the premutation on ovar-
ian function. The Washington National Primate Research Center
is currently generating a nonhuman primate transgenic model of
ovarian aging under the direction of Dr Eliza Curnow. Below, we
summarize the most mature animal model data from two recent
publications assessing the potential ovarian phenotypes of two
distinct mouse models engineered to have FMR1 PM repeats.
The female reproductive phenotypes of two transgenic mouse
lines harboring PM repeats have been characterized. Usdin and
colleagues inserted 130 CGG:CGG repeat lengths in the endoge-
nous FMR1 gene (referred to here as FXPM 130R; 130R), and
Sherman and colleagues characterized a mouse line carrying a
human premutation allele (derived from a yeast artificial chro-
mosome) of 90 repeats (referred to as mouse line TG206). The
female reproductive phenotypes that result from the two alleles
are summarized in Table 2.
Fertility and fecundity were the primarymeasures of the repro-
ductive status of the mouse lines, accompanied by analyses of
follicle number, survival, and ovarian gene expression versus
same-strain wild-type controls. In both mouse lines, fertility and
fecundity were largely normal, and only YAC90R females demon-
strated a slight but significant increase in the age at first litter,
and a decreased number of pups per litter (Lu et al., 2012). While
mouse age at first litter and slightly decreased fecundity in terms
of litter size do not have direct clinical correlates, these findings
hint at ovarian dysfunction in mice. To test whether the pre-
mutation negatively affects oocyte survival (and might thereby
accelerate the demise of ovarian function), follicles were counted
in both mouse strains.
While identical follicle counts were not performed on the two
mouse strains, in each case some differences were seen compared
to wild-type controls. Ovaries of the 130R mice were evaluated
at several postnatal time points, including mice 10–12 months
of age. Interestingly, only mice between 7 and 9 months of age
showed any difference in follicle numbers, a significant decrease
in primordial follicles compared to same-strain wild-type con-
trols. A decrease in primordial follicles was not seen, however,
in the mutants between 10 and 12 months. The follicle counts
performed on the YAC90R mice revealed that there were fewer
growing follicles in the ovaries of 25 day old and 9 week old
mutants versus controls. This corresponded to their delivering
fewer pups per litter than wild-type animals.
Despite the absence of an overt acceleration in follicle loss in
the YAC90R and 130R mice, there were some differences in fol-
licle development and granulosa cell survival that are suggestive
of dysfunction. Increased histomorphometric evidence of folli-
cle atresia (e.g., granulosa cell pyknosis) was seen in 130R PM
ovaries, which was matched by increased numbers of TUNEL-
positive apoptotic cells seen in the follicles of YAC90 PM ovaries.
Hoffman et al. performed a careful analysis of the number of
granulosa cells within individual 130R follicles and found that
there were fewer granulosa cells in mutant follicles (Hoffman
et al., 2012). That finding, along with (a) alterations in FMRP
distribution in the oocytes of 130R animals, (b) downregu-
lated mTOR signaling in whole ovaries of YAC90R mutants, (c)
decreased expression of genes required for ovulation in YAC90
ovaries, and (d) a general elevation in both estradiol and FSH in
during adulthood in YAC90R mice all are suggestive of compro-
mised follicle growth and aberrant function.
Whether such aberrant features are also present in ovarian
phenotypes that are associated with the FMR1 gene remains to
be seen, but such studies allow hypotheses to be generated and
subsequently tested upon human tissue.
It is important to remember that these mouse findings were
in the backdrop of overall similar numbers of intact follicles,
suggesting that follicles survive, but produce oocytes of poorer
“quality” in the presence of the FXPM. Determining whether
such a “quality” issue is also at work in women will be impor-
tant as these women seek out assisted reproductive treatment.
Further, our reliance on indirect measures to predict ovarian
reserve assumes that all follicles are essentially equal in their
production of reserve biomarkers like AMH. If the follicles of
women with FMR1-associated ovarian aging also contain fewer
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Table 2 | Mouse Models related to Ovarian Dysfunction and FMR1.
Mutant phenotype 130R (Hoffman et al., 2012) TG206/YAC90R (Lu et al., 2012)
Alteration(s) in
follicle number
Decreased numbers of primordial follicles in 7–9 month-old mice Decreased numbers of growing follicles in 25 day-old
and 9 week-old mice
Alteration(s) in
fecundity
Not evaluated Increased age at first litter, decreased number of pups
per litter
Alteration(s) in
hormone production
Not evaluated Hormone 8–10 weeks 15–22 weeks
Estradiol ↑ * **
FSH ↑ * ↑ *
LH ↓ n.s. ↓ n.s.
*P < 0.05, **not evaluated
Follicle death Increased histomorphometric evidence of follicle atresia in PM
ovaries; increased ubiquitylated proteins in PM oocytes.
Increased numbers of TUNEL-positive apoptotic cells in
PM ovaries
Alterations in follicle
growth
Granulosa cell number is decreased in growing follicles. Cumulus
granulosa cell number is also decreased in mature follicles.
mTOR pathway is downregulated in whole ovaries
(McLaughlin et al., 2011; Yu et al., 2011)
Alterations in gene
expression
Reduced expression of FMRP in PM granulosa cells. Redistribution
of FMRP to oocyte nucleus in PM (FMRP is cytoplasmic in wild-type
oocytes). Reduced CX36 expression.
Decreased expression of LH-induced ovulation-related
genes in PM ovaries versus wild-type controls.
Other abnormalities Presence of ovarian cysts; zona pellucida abnormalities. Reduced whole body weight in PM animals versus
wild-type controls.
and fewer healthy granulosa cells, it may be that their follicles
produce altered levels of hormones and our prediction(s) as to
their ovarian reserve may be less accurate. Continued evalua-
tion of these and future animal models, as well as more direct
approaches where follicle numbers are assessed directly in human
ovarian cortex (McLaughlin et al., 2011), will allow us to move
closer to understanding the biological mechanism(s) behind the
ovarian dysfunction seen in relation to the FMR1 gene.
DEVELOPMENT OF FUNCTIONAL FOLLICLES AND OOCYTES
FOR IN VITRO RESEARCH
As an alternative to both human research and animal models,
patient-specific induced pluripotent stem cells (iPSCs) derived
from adult somatic cells and differentiated into GC-like cells rep-
resent one novel possible option for generating an abundance of
material for research purposes without any invasive procedures.
Hayashi et al. showed that functional oocytes could be derived
from mouse iPSCs (Hayashi and Sayama, 2009). While this dif-
ferentiation method relied on in vivo co-culture with normal
mouse GCs transplanted under the ovarian bursa, the technique
showed the feasibility of reconstituting a follicle and generating a
functional oocyte from mouse iPSCs.
REPRODUCTIVE IMPLICATIONS IN HUMANS:
TRANSMISSION OF FXS
The likelihood that the CGG repeat expands in subsequent gen-
erations is important to families of women who carry the premu-
tation and wish to conceive. Thus, we review here the heritability
of the FMR1 gene. Additionally, the heritability of the genotype
is important in the context of ovarian reserve if future research
confirms an increased risk of infertility among women with a
particular repeat length.
The likelihood of a mother with the FMR1 premutation pass-
ing the full mutation to her children increases with the size of her
premutation allele. If the mother has approximately 100 repeats
of the CGG genetic sequence in the FMR1 gene, there is a nearly
100% chance that the repeat will expand and her child(ren) will
have the full mutation (Nolin et al., 2003, 2011). Risk of expan-
sion to the full mutation is moderated when the FMR1 CGG
repeat is interspersed with one or more AGG’s (Nolin et al., 2013).
Contractions of the FMR1 gene have also been reported (Reyniers
et al., 1993; Vits et al., 1994; Fisch et al., 1995; Brown et al., 1996;
Nolin et al., 1996). Premutation males very rarely pass on a full
mutation to their offspring (Ashley-Koch et al., 1998; Zeesman
et al., 2004).
The transmission of FMR1 alleles between mother-offspring
pairs (n = 238 pairs) is reported to be stable 93.4% of the time in
mothers with 45–54 CGG repeats (Cronister et al., 2008). Of the
6.6% that expanded within the intermediate range, the offspring
allele size never expanded beyond 60 repeats in 1 generation. The
smallest reported repeat size to expand to a full mutation in the
subsequent generation was 56; the grandmother of the affected
child had a repeat size of 52 (Fernandez-Carvajal et al., 2009). No
data are available on the stability of transmission of <45 CGG
repeats in females. Thus, while a woman with an intermediate size
CGG allele does not need to be concerned with having a child with
FXS, her daughter may be at increased risk for FMR1-associated
ovarian phenotypes, pending the results of future research.
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FMR1 GENETIC TESTING IN OB/GYN CLINICS
The American College of Medical Genetics (ACMG) testing
guidelines recommend FMR1 testing for “women with repro-
ductive or fertility problems associated with elevated FSH levels,
especially if there is a family history of POF, FXS, or undiag-
nosed mental retardation” (Sherman et al., 2005). The National
Society of Genetic Counselors and the Genetics Committee of
the American College of Obstetrics and Gynecology support
this recommendation (ACOG Committee of Genetics, 2010;
Finucane et al., 2012), as did participants in a collaborative project
between the MIND Institute Fragile X Research and Treatment
Center at the University of California at Davis, the National
Fragile X Foundation, and the Centers for Disease Control and
Prevention (McConkie-Rosell et al., 2007). Some authors have
called for further research to explore potential genetic counseling
issues for women ascertained in an infertility setting, includ-
ing the lack of prior experience with individuals with FXS, the
impact of unexpected findings on risk perceptions, regret or
anger that testing was not considered earlier in the infertility
evaluation process, and the shift of focus to include extended
family (McConkie-Rosell et al., 2005, 2007; Wittenberger et al.,
2007).
There is limited research on emotional reactions to and impact
on reproductive decision-making from FMR1 carrier testing.
A study of population screening for FMR1 premutations (Anido
et al., 2005, 2007) found that while women had active cop-
ing mechanisms, they also had concerns for the implications
of their carrier status for their children or grandchildren, and
the results impacted reproductive decisions whether in hind-
sight or for their own future. Among 20 women with DOR, the
emotional reactions to FMR1 testing were assessed using pre-
and post-test questionnaires (Pastore et al., 2008). While par-
ticipants in this study projected that learning they carried the
premutation would have little impact on how they felt about
themselves and their self-esteem, most projected that if they did
have the premutation they would feel better knowing there was
a medical explanation for their infertility. More recently, of 92
women with DOR undergoing FMR1 testing, 46% thought FMR1
premutations were “serious” before leaning their test results,
however many felt ambivalent or had positive feelings about
potentially being a carrier (Pastore et al., 2014c). Women who
had never been pregnant thought they were more likely to carry
the FMR1 premutation (p = 0.04) and more likely to think the
PM is a serious condition (p = 0.005) than women who had
been pregnant. Thus, clinicians can expect mixed reactions to
FMR1 carrier testing outside of FXS families, with additional
differences by her pregnancy history. A qualitative study was
conducted on the experience of FMR1 testing among seven
women with DOR and their husbands (Pastore et al., 2014b).
Women understood the reproductive implications of carrying
the FMR1 premutation, and hoped for a negative result. Being
offered a genetic test caused women to pause and re-think
their future reproductive plans. In contrast, the FMR1 test was
viewed as an additional source of information for their husbands
as opposed to raising concern regarding potential reproductive
ramifications.
FUTURE DIRECTIONS
Several areas of future research would be very beneficial. Selected
suggestions from the authors are noted below:
1. Infertility and FMR1: It is unknown if there are potential dif-
ferences in fertility treatment success by FMR1 CGG repeat.
More broadly, improved risk estimates for a variety of repro-
ductive endpoints would be greatly beneficial for counseling
women with a premutation allele. Analogously, risk estimates
for women with an intermediate allele would be very informa-
tive to patients, genetic counselors, and clinicians.
2. Ovarian hormones and FMR1: There is a lack of longitudi-
nal studies of reproductive hormones in FMR1 premutation
carriers. This would be an important step toward providing
biomarkers to be used in predicting the severity and timing
of ovarian aging in premutation carriers. This may or may
not be as informative in women with alleles or other repeat
lengths.
3. Genetic counseling in the OB/GYN clinical setting: Genetic
counseling issues related to the timing of counseling (pre-test,
post-test), the depth of counseling (clinician brief counseling,
separate session with genetic counselor, inclusion of family
members, etc.), and the content of counseling (e.g., howmuch
information is too much?) are needed.
CONCLUSION
This publication reviews the literature on the FMR1 gene and
selected phenotypes involving ovarian dysfunction. The litera-
ture is inconsistent on the association between the FMR1 repeat
length and infertility due to low ovarian reserve. Elevated levels
of FSH have been found in women who carry the premutation.
The literature on the relationship between AMH and the FMR1
CGG repeat length are contradictory, with variation in the study
designs and repeat length under investigation. Genetic counsel-
ing issues pertaining to reproduction and the FMR1 gene are
complex, both within and outside of FXS families.
In terms of animal models, two transgeneic mouse lines have
been characterized, which allow hypotheses to be tested in ways
that are impossible, impractical and/or unethical in humans.
Animal models are also under investigation using rats, fruit flies,
and nonhuman primates. Research with induced pluripotent
stem cells are also under development.
Clearly, further research is needed on the relationship between
the FMR1 gene and reproductive endpoints in women. The
inconsistency in the infertility and hormone study findings
increases the complexity of genetic counseling for women, and
makes it quite difficult for clinicians and patient to interpret the
results and anticipate health events. With the increased interest
in whole genome sequencing (Howard et al., 2013) and uptake
of direct-to-consumer genomic testing (Bloss et al., 2011), the
need for meaningful interpretation of genetic results will increase
dramatically in the near future. Animal models may provide a
means for exploration of the biological mechanism in ways not
possible among women, while larger cohort studies and/or more
creative study designs may provide the much-needed answers to
the impact of the FMR1 gene on women’s reproductive health.
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